326 episódios
- How can we best manage intermediate-risk bladder cancer to balance disease control, quality of life, and the growing range of treatment options? On this episode of the BackTable Urology Podcast, Dr. Ruchika Talwar interviews Dr. Charles “Chaz” Peyton about the challenges of treating recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer. They highlight the high recurrence but low progression risk, the often-underappreciated impact of repeated TURBTs on patient well-being, and the evolving landscape of office-based and chemoablative therapies.
---
Get the BackTable app
https://www.backtable.com/app
---
Timestamps
00:00 - Introduction05:58 - Comparing Office Ablation and OR TURBT08:26 - TURBT Impact on Quality of Life11:37 - Uncovering Hidden Patient Burdens and Costs14:44 - Integrating Chemoablation into Practice18:20 - ENVISION QoL Study Setup22:04 - Comparing TURBT Preferences27:40 - Counseling Risk-Averse Patients29:10 - Community Adoption Advice31:59 - Upcoming Clinical Trials35:28 - Biomarkers and Expanding Access36:23 - Final Thoughts and Closing Remarks
---
More about this episode
The conversation covers practical strategies like office-based surveillance and fulguration for small recurrences, identifying triggers for returning to the OR, and recognizing the hidden burdens of TURBT complications such as hematuria, incontinence, and unplanned ER visits. Dr. Peyton reviews the role of chemoablative options for selected patients, discusses trial data on patient-reported outcomes, and addresses the mixed evidence, high costs, and need for individualized decision-making. The episode also explores new intravesical and FGFR-targeted therapies, underscores the importance of cost-conscious adoption and biomarkers, and considers how management approaches must evolve, especially in community practice settings.
---
BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app Ep. 322 Social Media's Role in Urologic Education with Dr. Rena Malik & Dr. Fenwa Milhouse
06/08/2026 | 50minHow can you use social media to educate, empower, and inspire as a physician while staying true to your professional values? On this episode of BackTable Urology, guest host Dr. Maheetha Bharadwaj talks with Dr. Rena Malik and Dr. Fenwa Milhouse about building an authentic online presence that educates, inspires, and connects. The conversation highlights the power of visibility, the challenges of professional boundaries and misinformation, and the potential for social media to expand both patient outreach and career opportunities.
---
Get the BackTable apphttps://www.backtable.com/app
---
Timestamps
00:00 - Introduction04:17 - Getting Started on Social Media12:24 - Finding Your Niche17:04 - Being a Woman in Urology18:40 - Impact On Patient Care23:59 - Doctor-Patient Boundaries28:33 - Social Media Pitfalls38:53 - Creator Monetization45:58 - Advice for New Creators
---
More about this episode
They share insights from years of content creation, including tips for getting started, finding your niche, and balancing clinical work with online engagement. The discussion covers issues unique to women in urology, the impact of social media on patient care and doctor-patient boundaries, how to avoid burnout, and strategies for monetization and staying true to your message. The episode wraps up with practical advice for new creators and reflections on the privilege and responsibility of inspiring future urologists.
---
BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/appEp. 321 Exploring Hypospadias: Treatment Approaches and Patient Care with Dr. Vinaya Bhatia
04/08/2026 | 41minHypospadias can be surgically corrected early in life, but many patients drop out of care before puberty or adulthood, leaving important urinary and sexual health concerns unaddressed. On this episode of BackTable Urology, Dr. Arthi Hannallah and Dr. Nicco Passoni talk with Dr. Vinaya Bhatia about improving lifelong engagement for people with hypospadias. They highlight advances in surgical technique, the role of research, and how digital tools like the WYSH platform help keep patients and families connected to care.
---
Get the BackTable apphttps://www.backtable.com/app
---
Timestamps00:00 - Introduction04:22 - Hypospadias Overview and Symptom Chronology09:14 - Not A One Size Fits All: Developing WYSH13:28 - Reengaging Families and Patients20:04 - Adult Urology Sequelae25:08 - Demystifying Surgery and Improving Training34:00 - Centers of Excellence Debate36:56 - Future Goals and Wrap Up
---
More about this episodeThe discussion covers the development and impact of the WYSH platform, strategies for supporting long-term follow-up, and the learning curve of hypospadias surgery. Dr. Bhatia shares insights on better training, the creation of centers of excellence, and the importance of ongoing research and family engagement to improve quality of life at every stage.
---
ResourcesWorldwide Yearly Screening for Hypospadias: https://clinicaltrials.gov/study/NCT06966375
---
BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.► https://www.backtable.com/appEp. 320 Gem-iDRS for BCG Unresponsive Bladder Cancer: A Deep Dive with Dr. Sarah Psutka
31/07/2026 | 50minCan a drug-eluting bladder device change the treatment algorithm for BCG-unresponsive non–muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Ruchi Talwar interviews Dr. Sarah Psutka to explore the emerging role of a novel intravesical device that delivers sustained gemcitabine therapy for patients refusing or ineligible for cystectomy. They highlight new FDA-approved treatment options, real-world workflow considerations, and the clinical potential for continuous intravesical chemotherapy in a crowded therapeutic landscape.
---
Get the BackTable apphttps://www.backtable.com/app
---
This podcast is supported by
Johnson & Johnson
https://www.inlexzohcp.com/
---
Timestamps
00:00 - Introduction02:40 - Why Focus on TAR-20005:35 - Device Basics07:05 - Dosing Schedule Explained11:17 - SUNRISE-01 Trial Results15:07 - Patient Selection and Contraindications20:52 - Indications for Device Removal23:26 - Clinic Workflow Learning Curve25:56 - Tips for Insertion and Device Deployment28:52 - Cystoscopy Findings and Surveillance Protocol32:16 - Treatment Sequencing38:43 - Future Trial and Research Directions45:16 - Biomarkers, AI, and Personalizing Care46:35 - Cost, Supportive Care, and Patient Burden48:42 - Closing Thoughts
---
More about this episode
The conversation dives into patient selection, preparation, and side effect management for TAR-200, as well as the key findings from the SUNRISE-01 trial. Dr. Psutka discusses dosing schedules, when to remove the device, and how to handle complications like UTI, hematuria, and LUTS. The episode also covers surveillance protocols, the impact on clinic operations, and the importance of balancing vigilant cancer surveillance with patient burden. Finally, they touch on future directions, including biomarkers, AI-assisted pathology, and optimizing the timing of cystectomy and supportive care for a more personalized approach to NMIBC.
---
Resources
TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Studyhttps://ascopubs.org/doi/10.1200/JCO-25-01651 SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-muscle Invasive Bladder Cancer SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-mushttps://www.urotoday.com/conference-highlights/suo-2024/suo-2024-bladder-cancer/156723-suo-2024-sunrise-5-a-phase-iii-randomized-open-label-study-of-tar-200-compared-with-intravesical-chemotherapy-after-bacillus-calmette-guerin-in-recurrent-high-risk-non-muscle-invasive-bladder-cancer.htmlcle Invasive Bladder Cancer
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Resultshttps://ascopubs.org/doi/10.1200/JCO-25-02382
INLEXZO - SunRISe-3 Studyhttps://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-3-study
---
BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app- The definitive treatment for adult acquired buried penis is surgery, but successful treatment depends on having a well-coordinated network of patient support, multidisciplinary care teams, and reconstructive urologic surgery expertise. This episode of Backtable Urology overviews this multifaceted disease and dives into reconstructive surgery techniques, featuring Dr. George Koch and Dr. Paul Rusilko.
---
Get the BackTable apphttps://www.backtable.com/app
---
Timestamps
00:00 - Introduction04:10 - History of Buried Penis Treatment08:47 - Grafts Versus Flaps11:34 - Hidden Pathologies and Informed Consent13:46 - Research and Insurance Approval18:24 - Delayed Care and Disease Burden22:31 - Deciding When to Operate and Temporizing Procedures30:23 - Building Referral Networks33:13 - Future Directions36:42 - Infection Risk 41:15 - Technique Evolution45:57 - Preop Evaluation Essentials50:50 - Intraop Keys to Success and Graft Protection59:26 - Postop Pathway and Teamwork01:02:54 - W-Plasty Video Walkthrough01:13:52 - Wrap Up
---
More about this episode
The doctors explore the nuances of surgical treatment, emphasizing the importance of thorough preoperative counseling given the high likelihood of unexpected intraoperative findings and the need to adjust the surgical plan. Dr. Rusilko also discusses the broader burden of disease, including depression, strictures, occult penile cancer, and the high rate of postoperative complications, most of which are low grade. He stresses that earlier referral may improve patient care. The episode concludes with practical surgical tips, guidance on building a buried penis practice, strategies for setting realistic recovery expectations, and an in-depth case review of his novel W-plasty technique.
---
Resources
W-plasty: A novel procedure for the repair of adult-acquired buried penis https://doi.org/10.1016/j.urolvj.2023.100219
---
BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app
Mais podcasts de Ensino
Podcasts em tendência em Ensino
Sobre BackTable Urology
The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen here or on the streaming platform of your choice.
Sítio Web de podcastOuve BackTable Urology, Somos Infinitos e muitos outros podcasts de todo o mundo com a aplicação radio.pt

Obtenha a aplicação gratuita radio.pt
- Guardar rádios e podcasts favoritos
- Transmissão via Wi-Fi ou Bluetooth
- Carplay & Android Audo compatìvel
- E ainda mais funções
Obtenha a aplicação gratuita radio.pt
- Guardar rádios e podcasts favoritos
- Transmissão via Wi-Fi ou Bluetooth
- Carplay & Android Audo compatìvel
- E ainda mais funções


BackTable Urology
Leia o código,
descarregue a aplicação,
ouça.
descarregue a aplicação,
ouça.
BackTable Urology: Podcast do grupo





























